Takeda Pharmaceutical submitted a voluntary conditional takeover bid to purchase 100 percent of TiGenix, a biopharmaceutical company developing stem cell therapies for anti-inflammatory disease, for $628 million.
Motus GI Holdings, a medical device company, filed a $29 million initial public offering with the Securities Exchange Commission Jan. 5.
Exact Sciences expects to report net sales between $86.9 million and $87.9 million in its fourth quarter fiscal year 2017 results, raising the company’s year-round revenues to between $265.5 million and $266.5 million.
OrphoMed, a clinical-stage biopharmaceutical company, named Mark Sostek, MD, its next CMO.
More articles on gastroenterology:
Motus GI files for $29M initial public offering — 3 insights
GI leader to know: Dr. Donnie Smith of GI Associates of West Alabama
Exact Sciences to increase sales force by 200 employees in revenue boosting move — 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.